AgingResearch.NewsJoin free

Kyushu University

CompanyJapan

ROR

Kyushu University develops one asset, approved (pitavastatin in cholesterol). Mostly small molecule acting on lipid and ceramide metabolism, inflammation and HMGCR; based in Japan.

1
Asset
Furthest stage
Approved
14
Grants
3
Trials
1
Signal

Pipeline

1

  • pitavastatin

    PLGA nanoparticles deliver pitavastatin to inhibit HMGCR and target inflammatory pathways associated with retinal degeneration.

    Approved, Small molecule, Lipid and ceramide metabolism, Inflammation, cholesterol, heterozygous familial hypercholesterolemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials4
  • Signals9
  • Integrity notices10
  • Similar companies6

Intelligence